• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝脏组织病理学益处与微生物代价:口服万古霉素可减轻非酒精性脂肪性肝病,但会破坏盲肠微生物群。

Hepatic Histopathological Benefit, Microbial Cost: Oral Vancomycin Mitigates Non-Alcoholic Fatty Liver Disease While Disrupting the Cecal Microbiota.

作者信息

Çirkin Gül, Aydemir Selma, Açıkgöz Burcu, Çelik Aslı, Güler Yunus, Kiray Müge, Baykara Başak, Dinleyici Ener Çağrı, Öztürk Yeşim

机构信息

Department of Pediatric Gastroenterology Hepatology and Nutrition, Faculty of Medicine, Dokuz Eylul University, Izmir 35340, Türkiye.

Department of Histology and Embryology, Faculty of Medicine, Dokuz Eylul University, Izmir 35340, Türkiye.

出版信息

Int J Mol Sci. 2025 Sep 4;26(17):8616. doi: 10.3390/ijms26178616.

DOI:10.3390/ijms26178616
PMID:40943536
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12429848/
Abstract

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) encompasses a spectrum of liver conditions and involves gut-liver axis crosstalk. We aimed to evaluate whether oral vancomycin modifies liver injury and the cecal microbiota in a methionine-choline-deficient (MCD) diet model of NASH. Male C57BL/6J mice (n = 28) were block-randomized to four groups (n = 7 each) for 10 weeks: standard diet (STD); MCD diet; STD + vancomycin (VANC); and MCD + VANC (2 mg/mouse ≈ 50 mg/kg, every 72 h). After 10 weeks, liver tissues were analyzed for histological changes, cytokine levels [interleukin-6 (IL-6), interleukin-8 (IL-8), transforming growth factor beta 1 (TGF-β1)], and immunohistochemical markers [ubiquitin and cytokeratin 18 (CK18)]. Cecal microbiota composition was evaluated with 16S ribosomal RNA (rRNA) sequencing. The MCD reproduced key NASH features (macrovesicular steatosis, lobular inflammation). Vancomycin shifted steatosis toward a microvesicular pattern and reduced hepatocyte injury: CK18 and ubiquitin immunoreactivity were decreased in MCD + VANC vs. MCD, and hepatic IL-8 and TGF-β1 levels were lower in MCD + VANC vs. STD. Taxonomically, STD mice had -rich microbiota. The MCD diet alone reduced alpha diversity (α-diversity), modestly lowered Firmicutes and increased /. Vancomycin alone caused a much larger collapse in richness, depleting Gram-positive commensals and promoting blooms of , , , and . In the MCD + VANC group, vancomycin profoundly remodeled the microbiota, eliminating key commensals (e.g., ) and enriching , , and . Oral vancomycin in the MCD model of NASH improved liver injury markers and altered steatosis morphology, but concurrently reprogrammed the gut into a low-diversity, pathobiont-enriched ecosystem with near-loss of . These findings highlight a therapeutic trade-off-hepatic benefit accompanied by microbiome cost-that should guide microbiota-targeted strategies for NAFLD/NASH.

摘要

非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)涵盖了一系列肝脏疾病,涉及肠-肝轴的相互作用。我们旨在评估口服万古霉素是否能改善蛋氨酸-胆碱缺乏(MCD)饮食诱导的NASH模型中的肝损伤和盲肠微生物群。将雄性C57BL/6J小鼠(n = 28)随机分为四组(每组n = 7),持续10周:标准饮食(STD)组;MCD饮食组;STD + 万古霉素(VANC)组;以及MCD + VANC组(2 mg/小鼠≈50 mg/kg,每72小时一次)。10周后,对肝脏组织进行组织学变化、细胞因子水平[白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、转化生长因子β1(TGF-β1)]和免疫组化标志物[泛素和细胞角蛋白18(CK18)]分析。用16S核糖体RNA(rRNA)测序评估盲肠微生物群组成。MCD饮食重现了关键的NASH特征(大泡性脂肪变性、小叶炎症)。万古霉素使脂肪变性转变为微泡模式并减轻肝细胞损伤:与MCD组相比,MCD + VANC组中CK18和泛素免疫反应性降低,且与STD组相比,MCD + VANC组中肝脏IL-8和TGF-β1水平更低。从分类学角度来看,STD组小鼠具有丰富的微生物群。单独的MCD饮食降低了α多样性,适度降低了厚壁菌门并增加了……。单独使用万古霉素导致丰富度大幅下降,消耗了革兰氏阳性共生菌并促进了……、……、……和……的大量繁殖。在MCD + VANC组中,万古霉素深刻重塑了微生物群,消除了关键共生菌(如……)并富集了……、……和……。在NASH的MCD模型中,口服万古霉素改善了肝损伤标志物并改变了脂肪变性形态,但同时将肠道重新编程为低多样性、富含致病共生菌的生态系统,且……几乎消失。这些发现凸显了一种治疗权衡——肝脏获益伴随着微生物群代价——这应该指导针对NAFLD/NASH的微生物群靶向策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/8321852e327c/ijms-26-08616-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/4f42581c976c/ijms-26-08616-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/4c0d45645473/ijms-26-08616-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/745b5f766219/ijms-26-08616-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/94fb2b706eb6/ijms-26-08616-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/d461cc100158/ijms-26-08616-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/f58ab30dffad/ijms-26-08616-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/da5122f12720/ijms-26-08616-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/e75740f6c1ea/ijms-26-08616-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/920214f339d3/ijms-26-08616-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/204dc4dce8de/ijms-26-08616-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/8321852e327c/ijms-26-08616-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/4f42581c976c/ijms-26-08616-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/4c0d45645473/ijms-26-08616-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/745b5f766219/ijms-26-08616-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/94fb2b706eb6/ijms-26-08616-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/d461cc100158/ijms-26-08616-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/f58ab30dffad/ijms-26-08616-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/da5122f12720/ijms-26-08616-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/e75740f6c1ea/ijms-26-08616-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/920214f339d3/ijms-26-08616-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/204dc4dce8de/ijms-26-08616-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfee/12429848/8321852e327c/ijms-26-08616-g011.jpg

相似文献

1
Hepatic Histopathological Benefit, Microbial Cost: Oral Vancomycin Mitigates Non-Alcoholic Fatty Liver Disease While Disrupting the Cecal Microbiota.肝脏组织病理学益处与微生物代价:口服万古霉素可减轻非酒精性脂肪性肝病,但会破坏盲肠微生物群。
Int J Mol Sci. 2025 Sep 4;26(17):8616. doi: 10.3390/ijms26178616.
2
CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis.CXCL10 作为一种炎症介质和非酒精性脂肪性肝炎的非侵入性生物标志物发挥着关键作用。
J Hepatol. 2014 Dec;61(6):1365-75. doi: 10.1016/j.jhep.2014.07.006. Epub 2014 Jul 15.
3
HBOT alleviates diet-induced MASH by reprograming gut microbiota and liver metabolism in mice.高压氧疗法通过重新编程小鼠肠道微生物群和肝脏代谢来减轻饮食诱导的MASH。
Free Radic Biol Med. 2025 Sep;237:600-614. doi: 10.1016/j.freeradbiomed.2025.05.420. Epub 2025 May 31.
4
[Effect of Wenpi Pills on lipid metabolism in mice with non-alcoholic fatty liver disease induced by various diets].[温脾丸对不同饮食诱导的非酒精性脂肪肝小鼠脂质代谢的影响]
Zhongguo Zhong Yao Za Zhi. 2025 May;50(10):2730-2739. doi: 10.19540/j.cnki.cjcmm.20250120.401.
5
Herbal mixture of Platycodon grandiflorum, Cinnamomum cassia, and Asiasarum sieboldii extracts protects against NASH progression via regulation of hepatic steatosis, inflammation, and apoptosis.桔梗、肉桂和细辛提取物的草药混合物通过调节肝脏脂肪变性、炎症和细胞凋亡来预防非酒精性脂肪性肝炎的进展。
Phytomedicine. 2025 Jul 14;145:157077. doi: 10.1016/j.phymed.2025.157077.
6
Nuciferine Exerts Anti-Inflammatory Effects in Mice With Non-Alcoholic Steatohepatitis by Regulating the miR-23a-3p-SIRT1-NF-κB Pathway and Akkermansia muciniphila -Extracellular Vesicles.荷叶碱通过调节miR-23a-3p-SIRT1-NF-κB通路和嗜黏蛋白阿克曼氏菌细胞外囊泡对非酒精性脂肪性肝炎小鼠发挥抗炎作用。
Phytother Res. 2025 Aug;39(8):3508-3525. doi: 10.1002/ptr.8528. Epub 2025 Jul 4.
7
Puerarin Alleviates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease by Modulating Gut Microbiota.葛根素通过调节肠道菌群减轻高脂饮食诱导的非酒精性脂肪性肝病
Ann Clin Lab Sci. 2025 May;55(3):335-346.
8
Bovine lactoferrin intake prevents hepatic injury in a mouse model of non-alcoholic steatohepatitis induced by choline and methionine deficiency.摄入牛乳铁蛋白可预防胆碱和蛋氨酸缺乏诱导的非酒精性脂肪性肝炎小鼠模型中的肝损伤。
Drug Discov Ther. 2025 Sep 17;19(4):230-236. doi: 10.5582/ddt.2025.01047. Epub 2025 Aug 26.
9
Targeting fibrosis and steatosis: Nebivolol multi-pathway modulator ameliorates experimental non-alcoholic steatohepatitis in rats through AMPK/mTOR and TGF-β1/α-SMA pathways.靶向纤维化和脂肪变性:奈必洛尔多途径调节剂通过AMPK/mTOR和TGF-β1/α-SMA途径改善大鼠实验性非酒精性脂肪性肝炎
Bioorg Chem. 2025 Aug;163:108755. doi: 10.1016/j.bioorg.2025.108755. Epub 2025 Jul 16.
10
BDE-47 Disrupts Gut Microbiota and Exacerbates Prediabetic Conditions in Mice: Therapeutic Potential of Grape Exosomes and Antioxidants.BDE-47破坏小鼠肠道微生物群并加剧糖尿病前期状况:葡萄外泌体和抗氧化剂的治疗潜力
Toxics. 2025 Jul 29;13(8):640. doi: 10.3390/toxics13080640.

本文引用的文献

1
Unlocking the gut-liver axis: microbial contributions to the pathogenesis of metabolic-associated fatty liver disease.揭示肠-肝轴:微生物在代谢相关脂肪性肝病发病机制中的作用
Front Microbiol. 2025 Apr 25;16:1577724. doi: 10.3389/fmicb.2025.1577724. eCollection 2025.
2
The role of the interleukin family in liver fibrosis.白细胞介素家族在肝纤维化中的作用。
Front Immunol. 2025 Feb 10;16:1497095. doi: 10.3389/fimmu.2025.1497095. eCollection 2025.
3
Cytokeratin 18 in nonalcoholic fatty liver disease: value and application.非酒精性脂肪性肝病中细胞角蛋白 18:价值与应用。
Expert Rev Mol Diagn. 2024 Nov;24(11):1009-1022. doi: 10.1080/14737159.2024.2413941. Epub 2024 Oct 10.
4
Antibiotic effects on gut microbiota modulate diet-induced metabolic dysfunction-associated steatohepatitis development in C57BL/6 mice.抗生素对肠道微生物群的影响调节了C57BL/6小鼠饮食诱导的代谢功能障碍相关脂肪性肝炎的发展。
Genes Cells. 2024 Aug;29(8):635-649. doi: 10.1111/gtc.13134. Epub 2024 Jun 12.
5
Interleukins: Pathogenesis in Non-Alcoholic Fatty Liver Disease.白细胞介素:非酒精性脂肪性肝病的发病机制
Metabolites. 2024 Mar 6;14(3):153. doi: 10.3390/metabo14030153.
6
Nonalcoholic fatty liver disease in children and adolescents.儿童和青少年非酒精性脂肪性肝病
Clin Exp Pediatr. 2024 Feb;67(2):90-91. doi: 10.3345/cep.2023.00752. Epub 2024 Jan 24.
7
Ablation of the deubiquitinase USP15 ameliorates nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.去泛素化酶 USP15 的消融可改善非酒精性脂肪性肝病和非酒精性脂肪性肝炎。
Exp Mol Med. 2023 Jul;55(7):1520-1530. doi: 10.1038/s12276-023-01036-7. Epub 2023 Jul 3.
8
Impact of Vancomycin Treatment and Gut Microbiota on Bile Acid Metabolism and the Development of Non-Alcoholic Steatohepatitis in Mice.万古霉素治疗和肠道微生物群对胆汁酸代谢和小鼠非酒精性脂肪性肝炎发展的影响。
Int J Mol Sci. 2023 Feb 17;24(4):4050. doi: 10.3390/ijms24044050.
9
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD).非酒精性脂肪性肝病 (NAFLD) 的治疗进展。
Front Endocrinol (Lausanne). 2023 Jan 16;13:1087260. doi: 10.3389/fendo.2022.1087260. eCollection 2022.
10
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)的全球流行病学:系统评价。
Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.